Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Emerging Company Profile: Myeloid launches with programmed monocyte cell therapies for cancer

Myeloid launches with over $50 million from lead investor Newpath and monocyte cell therapies engineered to target cancer cells and coordinate antitumor immune functions.

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor